Triglyceride-Glucose Index (TyG) is associated with erectile dysfunction: A cross-sectional study.
IIEF-5
erectile dysfunction
insulin resistance
triglyceride-glucose index
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
24
06
2020
revised:
31
08
2020
accepted:
08
09
2020
pubmed:
17
9
2020
medline:
3
11
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
Erectile dysfunction (ED) is often associated with endocrine metabolic diseases such as metabolic syndrome (MetS) and diabetes mellitus (DM), in which insulin resistance (IR) plays a decisive role in pathology. Triglyceride-glucose index (TyG), a simple, inexpensive and easily accessible IR marker, is calculated by fasting serum glucose and triglyceride values. We aimed to reveal the relationship between TyG index and ED. Of 152 male patients, aged between 24-80 years, admitted to the urology outpatient clinic with complaining erectile insufficiency were evaluated. Liver function tests, complete blood count, fasting serum triglyceride, serum testosterone, fasting glucose, fasting insulin, and hemoglobinA1c (HbA1c) were analyzed. TyG index was calculated. All patients were requested to fill in the validated Turkish version of the 5-item International Index of Erectile Function (IIEF-5) survey. A total of 142 patients were included the study. ED was detected in 91 (64.1%) of the patients. BMI, fasting insulin level, fasting glucose level, IR, GGT, HDL, HbA1c, Triglyceride, TyG, DM, HT, and MetS status of the patients in ED group were statistically significantly higher compared to non-ED group (all P < .05). It was found that the cutoff value of TyG index for ED was 8.88 (AUC = 0.739, sensitivity 67%, specificity = 68.6%). In multivariate logistic regression analysis, age (OR = 1.07, 95% CI = 1026-1115, P = .002) and TyG index above 8.88 (OR = 3.865, 95% CI = 1686-8859, P = .001) were found as independent predictors of ED after accounting for BMI, serum total T and IR. TyG index might be useful in the diagnosis and follow-up of ED.
Sections du résumé
BACKGROUND
Erectile dysfunction (ED) is often associated with endocrine metabolic diseases such as metabolic syndrome (MetS) and diabetes mellitus (DM), in which insulin resistance (IR) plays a decisive role in pathology. Triglyceride-glucose index (TyG), a simple, inexpensive and easily accessible IR marker, is calculated by fasting serum glucose and triglyceride values.
OBJECTIVES
We aimed to reveal the relationship between TyG index and ED.
MATERIALS AND METHODS
Of 152 male patients, aged between 24-80 years, admitted to the urology outpatient clinic with complaining erectile insufficiency were evaluated. Liver function tests, complete blood count, fasting serum triglyceride, serum testosterone, fasting glucose, fasting insulin, and hemoglobinA1c (HbA1c) were analyzed. TyG index was calculated. All patients were requested to fill in the validated Turkish version of the 5-item International Index of Erectile Function (IIEF-5) survey.
RESULTS
A total of 142 patients were included the study. ED was detected in 91 (64.1%) of the patients. BMI, fasting insulin level, fasting glucose level, IR, GGT, HDL, HbA1c, Triglyceride, TyG, DM, HT, and MetS status of the patients in ED group were statistically significantly higher compared to non-ED group (all P < .05). It was found that the cutoff value of TyG index for ED was 8.88 (AUC = 0.739, sensitivity 67%, specificity = 68.6%). In multivariate logistic regression analysis, age (OR = 1.07, 95% CI = 1026-1115, P = .002) and TyG index above 8.88 (OR = 3.865, 95% CI = 1686-8859, P = .001) were found as independent predictors of ED after accounting for BMI, serum total T and IR.
CONCLUSION
TyG index might be useful in the diagnosis and follow-up of ED.
Substances chimiques
Biomarkers
0
Blood Glucose
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-244Informations de copyright
© 2020 American Society of Andrology and European Academy of Andrology.
Références
McCabe MP, Sharlip ID, Lewis R, et al. Risk Factors for Sexual Dysfunction Among Women and Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13(2):153-167.
Salonia A, Bettochi C, Carvalho J, et al. EAU Guidelines on Sexual and Reproductive Health 2020. In: European Association of Urology Guidelines. 2020 Edition, vol presented at the EAU Annual Congress Amsterdam 2020. European Association of Urology Guidelines Office, Arnhem, The Netherlands.
Rey-Valzacchi GJ, Costanzo PR, Finger LA, et al. Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study. J Androl. 2012;33(4):608-614.
Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. J Sex Med. 2013;10(12):3102-3109.
Patel JP, Lee EH, Mena CI, Walker CN. Effects of metformin on endothelial health and erectile dysfunction. Transl Androl Urol. 2017;6(3):556-565.
Chen S, Wu R, Huang Y, et al. Insulin resistance is an independent determinate of ED in young adult men. PLoS One 2013;8(12):e83951.
Toro-Huamanchumo CJ, Urrunaga-Pastor D, Guarnizo-Poma M, et al. Triglycerides and glucose index as an insulin resistance marker in a sample of healthy adults. Diabetes Metab Syndr. 2019;13(1):272-277.
Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402-2410.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
Corona G, Cipriani S, Rastrelli G, Sforza A, Mannucci E, Maggi M. High Triglycerides Predicts Arteriogenic Erectile Dysfunction and Major Adverse Cardiovascular Events in Subjects With Sexual Dysfunction. J Sex Med. 2016;13(9):1347-1358.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304.
Kang B, Yang Y, Lee EY, et al. Yoon KH (2017) Triglycerides/glucose index is a useful surrogate marker of insulin resistance among adolescents. Int J Obes. 2005;41(5):789-792.
Mazidi M, Kengne AP, Katsiki N, Mikhailidis DP, Banach M. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. J Diabetes Complications. 2018;32(3):266-270.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
Turunc TDSGS, Peskircioglu L. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Turkish J Urol. 2007;33(1):45-49.
Moon KH, Park SY, Kim YW. Obesity and Erectile Dysfunction: From Bench to Clinical Implication. World J Mens Health. 2019;37(2):138-147.
Guerrero-Romero F, Villalobos-Molina R, Jiménez-Flores JR, et al. Fasting Triglycerides and Glucose Index as a Diagnostic Test for Insulin Resistance in Young Adults. Arch Med Res. 2016;47(5):382-387.
Unger G, Benozzi SF, Perruzza F, Pennacchiotti GL. Triglycerides and glucose index: a useful indicator of insulin resistance. Endocrinol Nutr. 2014;61(10):533-540.
Lee SB, Kim MK, Kang S, et al. Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults. Endocrinol Metab (Seoul). 2019;34(2):179-186.
Vasques AC, Novaes FS, de Oliveira MS, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98-e100.
Russo GI, Cimino S, Fragalà E, et al. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. J Sex Med. 2014;11(8):2074-2082.
Morano S. Pathophysiology of diabetic sexual dysfunction. J Endocrinol Invest. 2003;26(3 Suppl):65-69.
Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metab Clin Exp. 2000;49(2):147-150.
Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22(6):423-436.
Kelly DM, Nettleship JE, Akhtar S, et al. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sci. 2014;109(2):95-103.
Binmoammar TA, Hassounah S, Alsaad S, Rawaf S, Majeed A. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSM open. 2016;7(3):2054270415622602.
Giugliano F, Maiorino M, Bellastella G, Gicchino M, Giugliano D, Esposito K. Determinants of erectile dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):204-209.
Francavilla S, Properzi G, Bellini C, Marino G, Ferri C, Santucci A. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. J Urol. 1997;158(5):1770-1774.
Contreras C, Sánchez A, Martínez P, et al. Impaired endothelin calcium signaling coupled to endothelin type B receptors in penile arteries from insulin-resistant obese Zucker rats. J Sex Med. 2013;10(9):2141-2153.
Boeri L, Capogrosso P, Pederzoli F, et al. Unrecognized Prediabetes Is Highly Prevalent in Men With Erectile Dysfunction-Results From a Cross-Sectional Study. J Sex Med. 2018;15(8):1117-1124.
Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636-2641.